Recombinant human CLL1 protein (CLL1-entrokinase-FC)
【No.】IRP009A | 【Protein name】 Recombinant human CLL1 protein |
【Gene Sequence Number/Expression Region】Q5QGZ9/(65-263AA) | 【Label position】N-terminal Human-Fc Tag |
【Restriction sites】Enterokinase | 【Packing specification】100μg/tube |
C- type lectin-like molecule . 1 (C-TypeLectin-LikeMolecule. 1-,-CLL. 1) , present in the peripheral blood and bone marrow myeloid cells and the majority of AML leukemic cells, but is also expressed in AML most of the CD34 + CD38 - , while the normal stem cells in the CD34 + CD38- not expressed on stem cells. The expression of leukemia cell surface antigen CLL-1 helps to distinguish myeloid leukemia from lymphoid leukemia. CLL-1 as LSC flag antigen, and help identify separation between normal stem cells and leukemic stem cells, leukemia immunophenotyping and AML of MRD have important value on the detector. This product is a CLL1-FC recombinant protein (the FC tag can be removed by enterokinase), which can be used for monoclonal antibody screening or antibody function verification.
Product name: Recombinant human CLL1 protein
Species: Human origin
Gene sequence number: Q5QGZ9
Tags: Human-Fc Tag
Tag site: N-terminal
Restriction site: enterokinase
Expression area: extracellular segment ( 65-263AA )
Host cell: 293F
Purity:> 90%
Purification method: Protein A column
Preservation system: PBS+20% glycerol
Storage conditions: -80℃
Illustration : Lane M on the left is the protein MW marker, Lane 1 is 15ug CLL1-Fc protein
Reference materials:
1. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia
2. C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity